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Over the last few years the intricate interaction between immune system and adipose tissue has been recognized. Indeed, it has 
been suggested that adipose tissue is not only a mere site of lipid and energy storage but can be considered as an “immune-
related” organ producing a series of molecules named adipokines. Among these, leptin, an adipocyte-derived cytokine-like 
hormone, seems to play a pivotal role in the regulation of several neuroendocrine and immune functions. In this review, we 
describe the effects of leptin in inflammation and immunity, and speculate on the possible modulation of the leptin axis in novel
adipopharmacotherapeutic settings. Biomed Rev 2006; 17: 53-62.
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INTRODUCTION 
The classic view of adipose tissue as a static reservoir of lipids 
necessary in time of reduced food availability in the environ-
ment is only a part of current adipobiology. Adipocytes as 
well as nonfat cells of the adipose tissue have been shown to 
secrete hormones, growth factors, cytokines and chemokines, 
collectively dubbed adipokines. These are necessary for vari-
ous biological functions, including the endocrine and immune 
function. Consequently, a series of novel hypotheses on the role 
of adipose tissue as a key regulator of immune function and 
as a secondary “immune organ” has been generated. Indeed, 
it is well known that immune cells, such as lymphocytes, 
macrophages and mast cells, are present in adipose tissue. 
Furthermore, adipose tissue cells are able to secrete a large 
number of adipokines classically considered of immune origin, 
such as cytokines and chemokines. 
Here, we present an overview of the immune functions 
mediated by leptin. Leptin is an adipokine which communi-
cates information on energy availability and thus influences
neuroendocrine and immune functions in animals and humans. 
Leptin primarily influences energy homeostasis and regulates
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neuroendocrine function in states of energy deficiency. As
a cytokine, leptin affects thymic homeostasis and, similar 
to other pro-inflammatory cytokines, promotes T helper 1
(Th1)-cell differentiation and cytokine production. We review 
recent advances on the role of leptin in the pathophysiology of 
immune responses during inflammation, leptin as a promising
target for adipopharmacology being also appreciated.
LEPTIN AND LEPTIN SIGNALING IN IMMUNE CELLS 
Several recent observations show that leptin is a hormone/cy-
tokine that is involved in immune-neuroendocrine crosstalk 
and functions as a key signal, coupling the metabolic axis to 
the immune system. Leptin, the product of the obese gene, 
is a 167-aminoacid peptide hormone mainly synthesized by 
adipocytes. It regulates body weight by stimulating energy 
expenditure through increased thermogenesis and by suppress-
ing food intake (1,2). In addition, leptin is sexually dimorphic, 
its serum concentration being higher in females than in males 
with similar body fat mass. Leptin belongs structurally to the 
family of long-chain helical cytokines and has a similarity 
with interleukin-6 (IL-6), IL-12, IL-15, granulocyte colony-
stimulating factor (G-CSF), oncostatin M (OSM), prolactin and 
growth hormone (3,4). The fact that leptin acts as a hormone 
and as a cytokine reinforces the concept that leptin links the 
endocrine to the immune system (3,4). The effects of leptin 
are mediated by the long form receptor. Briefly, the leptin
receptor (ObR) is a member of the class I cytokine receptor 
superfamily and has at least six isoforms as a result of alter-
native splicing. All isoforms share an identical extracellular 
ligand-binding domain. Leptin’s functional receptor (ObRb) 
is expressed not only in the hypothalamus, where it regulates 
energy homeostasis and neuroendocrine function, but also 
in each cell type of the innate and adaptive immunity (5-8). 
ObRb is involved in several downstream signal transduction 
pathways and has been identified in immune cells of both
animals and humans (5). Leptin binding to its functional re-
ceptor recruits Janus tyrosine kinases (JAK) and activates the 
receptor, which then serves as a docking site for cytoplasmic 
adaptors, such as signal transducer and activator of transcrip-
tion (STAT) (9). These translocate to the nucleus and induce 
expression of other genes, including negative regulators, such 
as the suppressor of cytokine signaling 3 (SOCS3) (10) and 
the protein tyrosine phosphatase 1B (11). A number of studies 
in human peripheral blood mononuclear cells (PBMC) have 
shown that, in addition to the JAK-2-STAT-3 pathway, which 
is an important pathway mediating leptin’s effect on immune 
cells, other pathways are also involved. The mitogen activated 
protein kinase (MAPK), the insulin receptor substrate-1 (IRS-
1), and the phosphatidylinositol 3’-kinase (PI3’K) pathways 
(12) are also important pathways that mediate leptin’s action on 
immune T cells (13). Moreover, in PBMC the MAPK pathway 
seems to mediate antiapoptotic effects (14) whereas the PI3’K 
pathway may be important in regulating glucose uptake (15). 
The role of Src associated in mitosis protein (Sam68), an RNA 
binding protein, regulator of RNA metabolism and effector of 
the PI3’K pathway, remains unclear, but it is currently thought 
to function as an adaptor protein by binding to activated STAT-
3 and to the p85 subunit of PI3’K (12).
THE ROLE OF LEPTIN IN INNATE AND ADAPTIVE IMMUNITY 
 In recent years, a number of studies investigated the effect of 
leptin on innate and adaptive immune responses (Fig. 1). In 
mouse monocytes/macrophages, leptin upregulates phagocytic 
function (16) via phospholipase activation (17) as well as 
proinflammatory cytokine secretion, such as tumor necrosis
factor-α (TNF-α), IL-6, and IL-12 (18,19). The augmenting 
effect of leptin in monocyte/macrophage function has also 
been confirmed in humans. Studies show that leptin stimulates
the proliferation of human circulating monocytes in vitro 
and upregulates expression of activation markers, such as 
CD25 (α-chain of IL-2 receptor), CD71 (transferrin receptor), 
CD69, and CD38, while further increasing the expression of 
other activation markers already present at high levels on the 
surface of resting monocytes, such as HLA-DR, CD11b, and 
CD11c (20). In polymorphonuclear cells of healthy subjects 
leptin stimulates reactive oxygen species production (8) and 
chemotaxis (21) via a mechanism which remains controversial 
and may or may not involve interaction with monocytes (22). 
In natural killer cells leptin is involved in all processes of cell 
development, differentiation, proliferation, activation, and 
cytotoxicity (23). The effect is mediated via STAT-3 activation 
and upregulated expression of perforin and IL-2 genes (6).
The effect of leptin in adaptive immunity of mice has also 
been well studied. This arm of the immune system is almost 
infinitely adaptable, mediated by lymphocytes that predomi-
nantly recognize peptide-MHC complexes and provides a 
broad range of immune responses against molecular structures 
other than carbohydrates. The effects of leptin on modulation 
of the immune response have been shown in leptin-deficient
(ob/ob) mice and in humans with congenital deficiency of lep-
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tin, in which both metabolic disturbances and immune abnor-
malities, including decreased inflammatory cytokine secretion
and thymic hypotrophy have been observed. These abnormali-
ties are reversed by the administration of recombinant leptin 
in both mice and humans. Studies in leptin receptor deficient
leptin-resistant db/db mice suggest that leptin may induce 
lymphopoiesis, as suggested by the reduced colony-forming 
potential under conditions favoring lymphoid expansion of 
bone marrow cells from db/db mice. Leptin also provides 
a survival signal for double positive CD4+CD8+ and single 
positive CD4+CD8- thymocytes during the energy consuming 
process of T-lymphocyte maturation (24) (Fig. 1). 
Studies in humans have further delineated the role of leptin 
in activation of lymphocytes. In contrast to monocytes/macro-
phages, leptin alone is unable to induce proliferation and acti-
vation of mature human peripheral blood lymphocytes unless it 
is co-administered with other non specific immunostimulants,
in which case leptin results in induction of early (CD69) and 
late activation markers (CD25, CD71) in both CD4+ and 
CD8+ lymphocytes (25). However, the proliferative effect 
of leptin seems to be specific only for distinct lymphocyte
subpopulations. More specifically, leptin induces proliferation
of naive CD4+CD45RA+ T cells, but inhibits proliferation of 
memory CD4+CD45RO+ T cells (26). At the functional level, 
leptin polarizes T helper (Th) cytokine production towards a 
proinflammatory (Th1, IFN-γ) rather than anti-inflammatory
Figure 1. Effects of leptin on innate and adaptive immune responses. Leptin promotes the generation, maturation and survival 
of thymic T cells and increases proliferation and IL-2 secretion by naive T cells. In addition, leptin induces a switch towards Th1 
immune response by increasing IFN-γ, TNF-α and IgG2a production and suppressing IL-4 secretion. On innate immunity, leptin 
promotes phagocytosis and oxygen radicals production. These effects sustain the immunity against pathogens and the acute 
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phenotype (Th2, IL-4) (5,25) (Fig. 1). These effects may be 
mediated by promoting T lymphocyte survival by upregulating 
expression of antiapoptotic proteins, such as Bcl-XL (27) and 
T-bet (26), and synergize with other cytokines in lymphocyte 
proliferation and activation, possibly via STAT3 (28,29).
LEPTIN, INFLAMMATION AND ENHANCED ANTOIMMUNE 
RESPONSES
The role of leptin in inflammation appears to be incompletely
understood. Endogenous leptin protects against TNF-medi-
ated toxicity. Ob/ob and db/db mice, as well as mice treated 
with a leptin-receptor antagonist, had increased sensitivity to 
the lethal effects of TNF. The addition of exogenous leptin 
protected against TNF-mediated toxicity in ob/ob mice, but 
did not increase the protective effect of endogenous leptin 
in wild-type mice (30). In the same way, animal models 
of leptin deficiency are protected from other toxic effects
of innate immunity-mediated inflammation (such as LPS,
zymosan-induced arthritis) (31). The mechanism for this 
presumed anti-inflammatory effect of leptin is unknown, but
an imbalance between proinflammatory (unchanged) and anti-
inflammatory cytokines (IL-10 and IL-1 receptor antagonist
are reduced) has been noted, raising the hypothesis that lep-
tin may alter the production of anti-inflammatory cytokines
by monocytes/macrophages via STAT-3 activation (32). In 
animals with adaptive immunity-mediated inflammation
(Con A-induced hepatitis (33,34), Clostridium difficile toxin
A-induced enteritis (35) or antigen-induced arthritis (36)), 
leptin deficiency has a protective effect, resulting in reduced
production of proinflammatory Th1 cytokines (34), and a shift
towards a Th2 response (36). In these models, ob/ob mice have 
less severe joint inflammation, reduced T cell proliferation,
lower concentrations of specific antibodies, reduced expres-
sion of Th1-type cytokines and a bias towards the production 
of Th2-type cytokines. Importantly, inflammatory cells may
themselves express and secrete leptin which may further foster 
the inflammatory process (37, 38).
Studies in mice: Several groups have investigated the 
susceptibility of ob/ob and db/db mice to experimentally-
induced autoimmune diseases (33-36,38-43). Susceptibility 
to experimental autoimmune encephalomyelitis (EAE), a 
model of multiple sclerosis (MS), has been investigated in 
ob/ob mice before and after recombinant leptin administration 
(40). Ob/ob mice are resistant to both actively and passively 
induced EAE but, consistent with leptin’s Th1 promoting 
activities, these mice become susceptible to the disease after 
leptin administration. Resistance to EAE in ob/ob mice is 
associated with a reduced proliferative response to myelin 
antigens and with an increased IL-4 response, whereas leptin 
replacement converted the Th2 response towards a Th1-type, 
leading to secretion of IFN-γ and to an IgG1-to-IgG2a isotype 
switch. Leptin administration to susceptible wild-type mice 
also worsened the disease by increasing both proinflammatory
cytokine levels and IgG2a production. These data were the first
to show the action of leptin in a central nervous system (CNS) 
model of autoimmunity in vivo. More recently, it has also been 
shown that in different strains of EAE susceptible mice, such 
as C57BL/6J and SJL/J, a serum leptin surge precedes disease 
onset and correlates with disease severity (38), inflammatory
anorexia and development of pathogenic T cell responses 
(38). Furthermore, infiltrating T cells and macrophages in the
CNS lesions stain positive for production of immunoreactive 
leptin, suggesting that leptin is also produced by immune cells 
during acute EAE.
The role of leptin and its receptor in the development of 
intestinal inflammation was recently described in an animal
model in which the usual confounding factors of altered im-
mune response, such as massive obesity, insulin-resistance, 
hyperglycaemia and hypercortisolemia were controlled for 
(43). It has been demonstrated that T cells from leptin-resistant 
db/db mice display reduced capacity to induce colitis, upon 
passive transfer in T cell-deficient mice (scid mice). Transfer 
of T cells from db/db mice induced delayed disease compared 
to transfer of wild-type cells. Histological examination of the 
colon early after the induction of disease revealed marked 
inflammation in mice injected with wild-type cells whereas
no inflammation was observed in mice receiving db/db cells. 
Lamina propria infiltrating lymphocytes (LPL) from both
wild-type and db/db mice showed no differences in terms of 
differentiation, expression of homing receptors and activa-
tion markers. Interestingly, the clearest difference was an 
increased rate of apoptosis of LPL derived from db/db mice 
and a reduced production of inflammatory cytokines such as
TNF-α, IFN-γ, IL-1, IL-6 and IL-18 and chemokines such as 
CXC-chemokine ligand 2 (CXCL2; macrophage inflamma-
tory protein 2, MIP2) and CC-chemokine ligand 3 (CCL3; 
macrophage inflammatory protein 1, MIP1). Of interest, recent
reports have shown that leptin secreted by the gastric mucosa 
is not completely degraded by proteolysis and can therefore 
reach the intestine in an active form, where it can control the 
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expression of sodium/glucose and peptide transporters on 
intestinal epithelial cells (46). As a result, leptin might have a 
dual function in the gastrointestinal track: (i) as a growth factor 
for the intestine, because of its involvement in the absorption 
of carbohydrates and proteins, and (ii) as a pivotal mediator 
of intestinal inflammation (44-46).
The role of leptin has also been investigated in spontane-
ous models of autoimmunity, such as type 1 diabetes mellitus 
(T1DM), in non-obese diabetic (NOD/LtJ) mice as well as in 
relation to the gender-related difference in susceptibility to 
autoimmune diseases. More specifically, early in life, leptin
administration significantly increases inflammatory infiltrates
in pancreatic islets, increases IFN-γ production by T cells, an-
ticipates the onset of T1DM, increases mortality and increases 
inflammatory infiltrates in pancreatic islets (42). Interestingly,
it has also been shown that mouse strains spontaneously devel-
oping autoimmune diseases, such as NOD/LtJ and interleukin 
IL-2-deficient mice, have increased basal serum leptin before
disease onset (42,47). Of note, both of these strains of mice 
also have reduced numbers of circulating regulatory T cells, 
important in the induction and maintenance of T cell toler-
ance and protection from autoimmunity (48). These lines of 
evidence suggest that leptin could also affect regulatory T cell 
function by reversing the suppressive activity of these cells 
against potentially autoreactive T cells. 
It is well known that the prevalence of autoimmune diseases 
(e.g., MS, rheumatoid arthritis, thyroiditis, and systemic lu-
pus erythematosus) is increased in females (56). In addition 
to genetic, hormonal, or other factors that may account for 
this difference, serum leptin levels are higher in females than 
males even after controlling for body mass index. Thus, the 
role of leptin in possibly mediating this phenomenon has 
been investigated. Female SJL/J mice are susceptible to EAE 
induction with myelin-derived peptides when compared with 
disease-resistant males (39). Factors which could account for 
resistance to EAE in males are an increased Th2 response to 
myelin and reduced IL-12 production by antigen presenting 
cells (APC). Treatment with recombinant leptin rendered male 
SJL/J mice susceptible to EAE induction and increased disease 
susceptibility in females. Treatment of males increased leptin 
levels to a concentration similar to that of EAE-susceptible 
females. These data suggest that leptin may prove to be one 
of the factors involved in the gender-related difference in 
susceptibility to autoimmune diseases and needs to be directly 
tested in humans. 
Studies in humans: Animal models of autoimmunity 
have consistently shown that leptin may induce, accelerate 
or potentiate experimentally induced (38-41) or spontaneous 
autoimmunity (42). In addition, the beneficial role of hypoca-
loric diets, which decrease serum leptin levels, in control of 
autoimmunity in humans has been well documented (49). 
Moreover, recent clinical reports on patients with autoimmune 
diseases demonstrate that high serum leptin levels may be 
a contributing etiopathogenic factor (50-52) or a marker of 
disease activity (53-55).
Increased peripheral secretion of leptin in humans is asso-
ciated with chronic inflammatory conditions, such as pelvic
endometriosis, nonalcoholic hepatitis, chronic pulmonary 
inflammation, inflammatory bowel disease, inflammatory
nephritis, Behcet's syndrome, thyroid-associated ophthal-
mopathy, T1DМ, rheumatoid arthritis, metabolic syndrome, 
and atherosclerosis (34-43). However, one group has reported 
increased plasma levels of leptin in patients with rheumatoid 
arthritis compared with healthy controls (43), other groups 
have not confirmed this association (47). In a similar manner,
the concentration of serum leptin has been found to be within 
the normal and/or physiological range in several inflamma-
tory conditions (48-50). Sampling and disease staging should 
be carefully evaluated when interpreting the results of these 
studies. It is nonetheless common to find an increase in leptin
concentration in the early phases of autoimmune diseases 
and before relapses (34-43). Intriguingly, food deprivation 
ameliorates the symptoms associated with some of these in-
flammatory conditions. For example, in rheumatoid arthritis,
fasting (and subsequent decrease of serum leptin) leads to 
improvement of disease activity and a shift towards Th2-cell 
responses (51). Fasting and/or caloric deprivation, or dietary 
changes in controlled trials in humans, can ameliorate clinical 
symptoms of autoimmune diseases such as IBD and MS, and 
similar changes are also effective in ameliorating disease in 
animal models of systemic lupus erythematosus and Sjögren's 
syndrome (37, 52-57). However, it must also be considered 
that the fall of leptin levels subsequent to fasting is not the 
only event associated with reduced caloric intake. Other hor-
monal and stress-response-related changes need to be taken 
into account to explain the final outcome (often resulting in
improvement of chronic inflammation).
Obesity, a hyperleptinemic state, is increasingly considered 
a chronic, low-grate inflammatory disease. It is associated with
progressive adipose tissue infiltration by macrophages (37,57)
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and mast cells that secrete proinflammatory cytokines (TNF-α, 
IL-1β and IL-6) which stimulate adipocytes to further secrete 
leptin. Tumor necrosis factor-α can induce insulin resistance, 
which could in turn perpetuate a vicious cycle of macrophage 
recruitment, production of proinflammatory cytokines, and
adipocyte dysfunction (58). It has thus been speculated that 
leptin, previously shown to be independently associated 
with several proinflammatory cytokines (59-61), and which
is increased during several inflammatory states, may foster
adaptive immunity-mediated inflammatory phenomena. We 
have recently directly tested this hypothesis by performing 
interventional studies involving recombinant methylated 
human leptin (rmetHuLeptin) administration to normal and 
obese humans to prove or disprove whether the above asso-
ciations reflect a causal role for leptin. We demonstrated that
rmetHuLeptin administration to increase circulating leptin 
levels to high physiologic or pharmacologic levels does not 
alter proinflammatory cytokine levels or immune function in
subjects with leptin sufficiency or excess (in obesity) (45). 
These data indicate that, similar to neuroendocrine function, 
the main role of leptin may be to regulate immune function in 
leptin deficient and not leptin sufficient states.
The beneficial role of fasting or hypocaloric diets, which
decrease serum leptin levels, in the control of autoimmunity 
in humans has been relatively well studied (49). A potential 
role for leptin is further supported by recent clinical reports on 
patients with autoimmune diseases, where high serum leptin 
levels may be a contributing pathogenic factor (50-52) or 
marker of disease activity (53-55). Moreover, in patients with 
rheumatoid arthritis, fasting for 7 days was sufficient to induce
clinical and laboratory evidence of disease improvement (62), 
but a 7-day ketogenic diet showed only moderate clinical effect 
(63), indicating that the role of leptin in autoimmunity is still 
incompletely understood. 
LEPTIN AND CHRONIC INFLAMMATION:  
THE ENDOMETRIOSIS MODEL
Endometriosis is a benign gynecological disease characterized 
by implantation and growth of endometrial tissue outside the 
uterus, mainly in the peritoneal cavity. Endometriosis is a good 
example of a chronic inflammatory disease, as it is sustained
by multiple repeated events that lead to the coexistence of all 
signs of Galenus-Virchow’s description of inflammation: ru-
bor, calor, dolor, tumor, and functio laesa. The most accredited 
pathogenetic hypothesis of endometriosis involves endometrial 
tissue transported to the peritoneal cavity throughout the tubes 
(retrograde menstruation), adherence to the peritoneal wall, 
followed by proliferation and formation of endometriotic le-
sions (64). Since retrograde menstruation occurs in almost all 
women, “permissive” factors must operate to allow develop-
ment of disease. Leptin may well be one of these factors as it 
promotes angiogenesis and induces the expression of Bcl-2, 
intercellular adhesion molecule 1, and matrix metalloprotei-
nases (65). Interestingly, endometrial cells of women with 
endometriosis have altered expression of above mentioned 
molecules, and also increased secretion of TNF-α, IL-1, and 
IL-6 by peritoneal macrophages (66). More importantly, leptin 
concentrations in serum and peritoneal fluid of patients with
pelvic endometriosis are increased, and the endometriotic tis-
sue expresses the long signaling form of the leptin receptor 
(67). It has been suggested that leptin is central in favoring 
implantation, growth, and maintenance of ectopic endometrial 
cells after retrograde menstruation and in locally promoting 
neoangiogenesis and invasion of the extracellular matrix via 
increased expression of matrix metalloproteinases.
ADIPOPHARMACOLOGY OF LEPTIN: IMMUNOTHERAPEUTIC 
APPLICATIONS, CURRENT EVIDENCE AND HYPOTHESES 
Leptin-based therapy is currently administered to a few cases 
of genetically leptin-deficient individuals and to morbidly 
obese non-leptin-deficient patients to reduce their food intake.
This treatment is effective in genetically leptin-deficient in-
dividuals in restoring some of the impaired neuroendocrine 
functions and in controlling food intake and reproductive 
function. Conversely, in non-leptin-deficient obese patients
the effect of leptin administration is modest on food intake 
and weight loss, probably due to leptin receptor desensitiza-
tion caused by the already high circulating leptin. Although 
the above are the only therapeutic uses of leptin in humans, 
additional clinical applications could be hypothesized on the 
basis of the immunoregulatory properties of leptin on CD4+ 
T cells. In immunodeficiency associated with reduced food
intake, such as anorexia nervosa or HIV-1 infection, leptin 
levels as well as CD4+ T cell numbers and function do not 
increase and are often reduced (68-72). Leptin administration 
might be suggested to provide help for immunoreconstitution 
via increased thymic T cell output and cell-mediated Th1 
immune responses. Increased Th1 responses may also be 
envisaged for resistant tuberculosis in immunocompromised 
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hosts and in the context of vaccination protocols to boost 
immune responses. In animals with reduced leptin levels, 
which have reduced delayed-type hypersensitivity responses 
and increased Th2 responses (5), the administration of leptin 
completely restores delayed-type hypersensitivity reactivity 
as well as the Th1 phenotype. A possible side effect of leptin 
therapy in these immunocompromised hosts is the inhibition 
of food intake due to leptin’s action on the hypothalamus. This 
side effect can be avoided by using leptin receptor agonists 
unable to cross the blood brain barrier. With this approach it 
would be possible to have the effects of leptin on peripheral 
tissues, including the immune system, and not on food intake. 
Moreover, modulation of circulating leptin levels may be 
considered as a new possible strategy to intervene on some 
inflammatory and autoimmune conditions. This approach
could easily be applicable, as it would be possible to reduce 
circulating leptin by caloric deprivation, thus overcoming some 
disadvantages of other cytokine-based therapies. In addition 
to starvation, diets rich in polyunsaturated fatty acids (n-3, 
fish oil), and low in saturated fatty acids, and/or zinc-free,
could also be considered to diminish circulating leptin with 
little effects on body fat composition (73,74). Clinical trials 
involving starvation to modulate proinflammatory responses
in human autoimmune diseases have already been reported as 
successful (75). A better understanding of the role of leptin 
in the modulation of inflammation and autoimmunity is a yet
little explored, but promising adipopharmacological approach. 
It may possibility lead to the addition of novel interesting 
tools to the armamentarium of the current immunotherapies 
for inflammation and autoimmune conditions.
CONCLUSION
There are still many questions concerning the role of several 
molecules, including leptin and other adipokines, at the inter-
face between metabolism and immunity in the regulation of 
these two systems. Significant leaps of knowledge have been
done in recent years in expanding the field of adipobiology and
adipopharmacology of such molecules. While new information 
is unveiling the complexity connecting metabolism and im-
munity, further research is still needed. This should consider 
the adipose tissue an active participant in the regulation of 
essential body processes, with prominent roles particularly in 
the balance of inflammation and immune homeostasis.
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